Publications by authors named "V G Goldschmidt"
Article Synopsis
- The study investigates the relationship between Philadelphia negative myeloproliferative neoplasms (MPN Ph (-)) and monoclonal gammopathies (MG), noting a 3 to 14% occurrence and higher thrombosis risk in patients with both conditions.
- A retrospective analysis reviewed clinical data of 144 patients diagnosed with MPN Ph (-) between 2015 and 2020, identifying 6 patients, all female, who also had MG.
- Findings showed that while the occurrence of MG in this group was expected for their age, there were concerns about thrombotic events, prompting calls for more research on the link between these conditions.
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, complement-associated, haematological disorder. The level of knowledge about the disease and its management varies around the world. This narrative review provides an overview of available clinical data on PNH in Latin America (LATAM).
View Article and Find Full Text PDFArticle Synopsis
- Antibody-drug conjugates (ADCs) are a promising cancer treatment that combines targeted monoclonal antibodies with potent drugs, relying on the expression levels of target proteins in cancer cells for effectiveness.
- This review analyzes clinical trial results from January 2019 to May 2023, highlighting approved ADCs that show efficacy even in tumors with low levels of target protein expression.
- It emphasizes the challenges in accurately assessing target protein levels due to inconsistent evaluation methods and the complexity of ADC behavior in the body, advocating for standardized approaches to improve future ADC therapies.
Purpose: With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis-associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients.
View Article and Find Full Text PDFT-cell engagers (TCE) are cancer immunotherapies that have recently demonstrated meaningful benefit for patients with hematological malignancies and solid tumors. The anticipated widespread use of T cell engagers poses implementation challenges and highlights the need for guidance to anticipate, mitigate, and manage adverse events. By mobilizing T-cells directly at the contact of tumor cells, TCE mount an obligatory and immediate anti-tumor immune response that could result in diverse reactions and adverse events.
View Article and Find Full Text PDF